Litcius/Paper detail

Sars-CoV-2 infection in patients with cystic fibrosis. An overview.

Valentina Fainardi, Francesco Longo, Alfredo Chetta, Susanna Esposito, Giovanna Pisi

2020PubMed19 citationsDOIOpen Access PDF

Abstract

The novel coronavirus SARS-CoV-2 was first identified in China in December 2019 and has since spread worldwide. People with Cystic Fibrosis (CF) have reduced survival mainly because of respiratory failure due to chronic pulmonary infections. Therefore, CF patients should be considered to have an increased risk of developing severe manifestations in case of SARS-CoV-2 infection. Surprisingly, the results of recent studies concerning SARS-CoV-2 infection in patients with CF show that in these patients the infection rate was lower than that of the general population. Various factors have been considered to explain a possible protective effect of CF against SARS-CoV-2 infection.

Topics & Concepts

Cystic fibrosisMedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PopulationLung infectionCoronavirusCoronavirus disease 2019 (COVID-19)Chronic infectionIntensive care medicineImmunologyInternal medicineLungDiseaseEnvironmental healthInfectious disease (medical specialty)Immune systemCystic Fibrosis Research AdvancesLong-Term Effects of COVID-19COVID-19 Clinical Research Studies
Sars-CoV-2 infection in patients with cystic fibrosis. An overview. | Litcius